Study of survodutide for liver disease NASH/MASH with fibrosis
Part of Digestive system clinical trials.
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with NASH or MASH (a type of fatty liver disease)
- Your weight has been stable (not changed more than 5%) in the last 3 months
- You are willing to keep a stable diet and activity level during the study
- You do not have cirrhosis (severe scarring) or other serious liver diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called pemvidutide to see if it can reduce liver scarring in people with MASH (a liver condition linked to excess weight and metabolic issues). It may help improve liver health and potentially slow or reverse the condition.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This study tests an investigational drug called ALN-CIDEB for people with MASH, a liver condition linked to metabolic issues, that has caused moderate liver scarring. The goal is to see if the drug can reduce liver damage and improve liver health.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.